Correlation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication

Psychiatry Research

Volumn 178, Issue 1, 2010, Pages 68-72

  Miljević, Čedo ^a   Nikolić Kokić, Aleksandra ^b   Saičić, Zorica S ^b   Milosavljević, Maja ^a   Blagojević, Duško ^b   Toševski, Dušica Lečić ^a   Jones, David R ^c   Spasić, Mihajlo P ^b  

^a INSTITUTE OF MENTAL HEALTH   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Catalase; Erythrocytes; Glutathione peroxidase; Glutathione reductase; Oxidative stress; Schizophrenia; Superoxide dismutase

Indexed keywords

CATALASE; CHLORPROMAZINE; FLUPHENAZINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HALOPERIDOL; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; MALE; NEGATIVE FEEDBACK; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SCHIZOPHRENIA TYPE 1; SCHIZOPHRENIA TYPE 2;

EID: 77955301261     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.10.038     Document Type: Article

References (56)

1. Abdalla, D.S., Monteiro, H.P., Oliveira, J.A., Bechara, E.J., 1986. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clinical Chemistry 32, 805-807.
2. Akyol, O., Herken, H., Uz, E., Fadillioǧlu, E., Unal, S., Söǧüt, S., Ozyurt, H., Savaş, H.A., 2002. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Progress in neuro-psychopharmacology & Biological Psychiatry 26, 995-1005.
3. Altuntas, I., Aksoy, H., Coskun, I., Caykoylu, A., Akcay, F., 2000. Erythrocyte superoxide dismutase and glutathione peroxidase activities and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clinical Chemistry Laboratory Medicine 38, 1277-1281.
4. Basso, M.R., Nasrallah, H.A., Olson, S.C., Bornstein, R.A., 1997. Cognitive deficits distinguish patients with adolescent and adult-onset schizophrenia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 10, 107-112.
5. Basso, M.R., Nasrallah, H.A., Olson, S.C., Bornstein, R.A., 1998. Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia. Schizophrenia Research 31, 99-111.
6. Ben-Shachar, D., Zuk, R., Gazawi, H., Ljubuncic, P., 2004. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochemical Pharmacology 67, 1965-1974.
7. Beutler, E., 1982. Catalase. In: Beutler, E. (Ed.), Red Cell Metabolism, A Manual of Biochemical Methods. Grune and Stratton, Inc, New York, pp. 105-106.
8. Blagojević, D., Buzadžić, B., Korać, B., Saičić, Z.S., Radojičić, R., Spasić, M.B.,1998. Seasonal changes in the antioxidant defense in ground squirrel (Citellus citellus): possible role of GSH-Px. Journal of Environmental Pathology, Toxicology and Oncology 17, 241-250.
9. Cahn, W., Hulshoff Pol, H.E., Bongers, M., Schnack, H.G., Mandl, R.C., Van Haren, N.E., Durston, S., Koning, H., Van Der Linden, J.A., Kahn, R.S., 2002. Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures. The British journal of psychiatry Supplement 43, 66-72.
10. Crow, T.J., 1990. Temporal lobe asymmetries as the key to the etiology of schizophrenia. Schizophrenia Bulletin 16, 433-443.
11. De Lisi, L.E., Sakuma,M.,Maurizio,A.M.,Relja,M.,Hoff, A.L., 2004.Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatric Research 130, 57-70.
12. Djujić, I., Jozanov-Stankov, O., Demajo, M., 2003. Oxidative stress and antioxidant defense markers in the population of Serbia and Montenegro. Iugoslavica Physiologica et Pharmacologica Acta 39, 121-128.
13. Do, K.Q., Trabesinger, A.H., Kirsten-Krüger, M., Lauer, C.J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., Cuénod, M., 2000. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 12, 3721-3728.
14. Drabkin, D., Austin, H., 1935. Spectrophotometric studies: preparations from washed blood cells. Journal of Biological Chemistry 112, 51-55.
15. du Bois, T.M., Deng, C., Huang, X.F., 2005. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Progress in Neuro Psychopharmacology & Biological Psychiatry 29, 878-888.
16. Fendri, C., Mechri, A., Khiari, G., Othman, A., Kerkeni, A., Gaha, L., 2006. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 32, 244-252.
17. Glatzle, D., Vuilleumier, J.P., Weber, F., Decker, K., 1974. Glutathione reductase test with whole blood a convenient procedure for the assessment of the riboflavin status in humans. Experientia 30, 665-667.
18. Guemouri, L., Artur, Y., Herbeth, B., 1991. Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood. Clinical Chemistry 37, 1932-1937.
19. Gur, R.E., Cowell, P., Turetsky, B.I., Gallacher, F., Cannon, T., Bilker, W., Gur, R.C., 1998. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry 55, 145-152.
20. Harman, D., 1972. Free radical theory of aging: dietary implications. The American Journal of Clinical Nutrition 25, 839-843.
21. Herken, H., Uz, E., Ozyurt, H., Sogut, S., Virit, O., Akyol, O., 2001. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular Psychiatry 6, 66-73.
22. Hinkle, D.E.,Wiersmam,W., Jurs, S.G., 1994. Applied Statistics for the Behavioral Sciences. Houghton Mifflin, Boston, MA.
23. Ho, B.C., Andreasen, N.C., Nopoulos, P., Arndt, S., Magnotta, V., Flaum, M., 2003. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 60, 585-594.
24. Iritani, S., 2007. Neuropathology of schizophrenia: a mini review. Neuropathology 27, 604-608.
25. Jovic, M., Korac, B., Blagojevic, D., Buzadjic, B., Saicic, Z.S., Spasic, M.B., Petrovic, V.M., 1995. In: Maksimovic, Z.J., Petrovic, V.M., Spuzic, I.V., Gasic, M.J. (Eds.), The activity of Se-dependent GSH-Px in patients with schizophrenia.. Conference on Selenium, Scientific Meetings, vol. LXXVIII. Serbian Academy of Sciences and Arts, Belgrade, Yugoslavia, pp. 195-203.
26. Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
27. Kowald, A., Kirkwood, T.B., 1996. A network theory of ageing: the interactions of defective mitochondria, aberrant proteins, free radicals and scavengers in the ageing process. Mutation Research 316, 209-236.
28. Kuloglu, M., Ustundag, B., Atmaca, M., Canatan, H., Tezcan, A.E., Cinkilinc, N., 2002. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function 20, 171-175.
29. Lane, N., 2002. Oxygen: The Molecule that made the World. Oxford University Press, Oxford, UK.
30. Lane, N., 2003. A unifying view of ageing and disease: the double-agent theory. Journal of Theoretical Biology 225, 531-540.
31. Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D., Bilder, R., 2001. Longitudinal study of brain morphology in first episode schizophrenia. Biology Psychiatry 49, 487-499.
32. Mahadik, S., Mukherjee, S., 1996. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research 19, 1-17.
33. Manley, B.F.J., 1986. Multivariate Statistical Methods. A Primer. Chapman and Hall, London.
34. Michelson, A.M., 1987. Medical aspects of superoxide dismutase. Life Chemistry Reports 6, 1-142.
35. Michelson, A.M., 1998. Selenium glutathione peroxidase: some aspects in man. Journal of Environmental Pathology, Toxicology and Oncology 17, 233-239.
36. Misra, H.P., Fridovich, I., 1972. The role of superoxide anion in the autoxidation of epinephrine and a sample assay for superoxide dismutase. Journal of Biological Chemistry 247, 3170-3175.
37. Mukherjee, S., Mahadik, S.P., Scheffer, R., Correnti, E.E., Kelkar, H., 1996. Impaired antioxidant defence at the onset of psychosis. Schizophrenia Research 19, 19-26.
38. Nikolić-Kokić, A., Stević, Z., Stojanović, S., Blagojević, P.D., Jones, D.R., Pavlović, S., Niketić, V., Apostolski, S., Spasić, M.B., 2005. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Report 10, 265-270.
39. Nikolić-Kokić, A., Stević, Z., Blagojević, D., Davidović, D., Jones, D.R., Spasić, M.B., 2006. Alterations in anti-oxidative defense enzymes in erythrocytes from SALS and FALS patients. Clinical Chemistry and Laboratory Medicine 44, 589-593.
40. Paglia, D.E., Valentine, W.N., 1967. Studies on the quantitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine 70, 74-77.
41. Pantelis, C., Yücel, M.,Wood, S.J., Velakoulis, D., Sun, D., Berger, G., Stuart, G.W., Yung, A., Phillips, L., McGorry, P.D., 2005. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin 31, 672-696.
42. Parthasarathy, S., Khan-Merchant, N., Penumetcha, M., Khan, B.V., Santanam, N., 2001. Did the antioxidant trials fail to validate the oxidation hypothesis? Current Atherosclerosis Reports 3, 392-398.
43. Ranjekar, P.K., Hinge, A., Hegde, M.V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U.V., Debsikdar, V.B., Mahadik, S.P., 2003. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 121, 109-122.
44. Reddy, R., Sahebarao, M.P., Mukherjee, S., Murthy, J.N., 1991. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biological Psychiatry 30, 409-412.
45. Rukmini, M.S., D'Souza, B., D'Souza, V., 2004. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian Journal of Clinical Biochemistry 19, 114-118.
46. Sirota, P., Gavrieli, R., Wolach, B., 2003. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry research 121, 123-132.
47. Smythies, J., 2000. Redox aspects of signaling by catecholamines and their metabolites. Antioxidants & Redox Signaling 2, 575-583.
48. Tsuchihashi, M., 1923. Zϋr Kenntnis der Blutkatalase. Biochemische Zeitschrift 140, 65-74.
49. Tylec, A., Jarzab, A., Stryjecka-Zimmer, M., Wójcicka, A., 2007. Stress oxidative in schizophrenia Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 23, 74-77.
50. van Haren, N.E., Pol, H.E., Schnack, H.G., Cahn,W., Brans, R., Carati, I., Rais, M., Kahn, R.S., 2008. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biology Psychiatry 63, 106-113.
51. World Health Organization (WHO), 1992. International Statistical Classification of Diseases and Related Health Problems. Tenth revision, Geneva.
52. Yanik, M., Vural, H., Kocyigit, A., Tutkun, H., Zoroglu, S.S., Herken, H., Savas, H.A., Koylu, A., Akyol, O., 2003. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology 47, 61-65.
53. Yao, J.K., Reddy, R., McElhinny, L.G., van Kammen, D.P., 1998. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research 32, 1-8.
54. Yao, J.K., Reddy, R.D., van Kammen, D.P., 2001. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15, 287-310.
55. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C., 2003. The effect of risperidone treatment on superoxide dismutase in schizophrenia. Journal of Clinical Psychopharmacology 23, 128-131.
56. Zhang, X.Y., Tan, Y.L., Cao, L.Y., Wu, G.Y., Xu, Q., Shen, Y., Zhou, D.F., 2006. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 81, 291-300.